My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

17.29 +0.26 (+1.53%)

Streaming Delayed Price Updated: 11:01 AM EDT, Oct 13, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	199,839
Open	17.04
Bid (Size)	17.28 (1)
Ask (Size)	17.30 (2)
Prev. Close	17.03
Today's Range	16.82 - 17.32
52wk Range	12.72 - 32.10
Shares Outstanding	114,998,871
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IMMUNOVANT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 17, 2025

From Kahn Swick & Foti, LLC

Via GlobeNewswire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

September 12, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Performance

YTD	-31.4%	-31.4%
1 Month	+7.0%	+7.0%
3 Month	-7.0%	-7.0%
6 Month	+12.1%	+12.1%
1 Year	-41.3%	-41.3%

More News

Why Immunovant Stock Blasted Higher Today

September 03, 2025

Via The Motley Fool

Four Stocks To Watch This Week - Monday, Sep. 23

September 23, 2024

Via Talk Markets

Top 2 Health Care Stocks That May Collapse This Quarter

September 09, 2024

Via Benzinga

IMVT Investors Have Opportunity to Join Immunovant, Inc. Fraud Investigation with the Schall Law Firm

August 27, 2025

From The Schall Law Firm

Via Business Wire

IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc. - IMVT

August 13, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Immunovant Posts 34% R&D Jump in Q1

August 11, 2025

Via The Motley Fool

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

June 20, 2025

Via ACCESS Newswire

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence

May 29, 2025

Via Stocktwits

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

May 21, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

April 22, 2025

Via Benzinga

Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift

April 21, 2025

Via Investor's Business Daily

Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated

April 21, 2025

Via Stocktwits

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

April 21, 2025

From Roivant Sciences

Via GlobeNewswire

Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data

March 19, 2025

Via Benzinga

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.

March 19, 2025

Via Investor's Business Daily

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

March 19, 2025

Via Benzinga

Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity

March 04, 2025

Via Investor's Business Daily

High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What

January 19, 2025

Via Talk Markets

Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases

September 25, 2024

Via Investor's Business Daily

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

September 09, 2024

Via Benzinga

Roivant Provides Update on Graves’ Disease Development Program

September 09, 2024

From Roivant Sciences

Via GlobeNewswire

After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay

May 30, 2024

Via Investor's Business Daily

IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024

May 29, 2024

Via InvestorPlace

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?

Yes, Immunovant, Inc. - Common Stock is publicly traded.

What exchange does Immunovant, Inc. - Common Stock trade on?

Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Immunovant, Inc. - Common Stock?

The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market

What is the current price of Immunovant, Inc. - Common Stock?

The current price of Immunovant, Inc. - Common Stock is 17.29

When was Immunovant, Inc. - Common Stock last traded?

The last trade of Immunovant, Inc. - Common Stock was at 10/13/25 11:01 AM ET

What is the market capitalization of Immunovant, Inc. - Common Stock?

The market capitalization of Immunovant, Inc. - Common Stock is 1.99B

How many shares of Immunovant, Inc. - Common Stock are outstanding?

Immunovant, Inc. - Common Stock has 2B shares outstanding.

Recent Quotes

Symbol	Price	Change (%)
GOOG	241.06	+3.57 (1.50%)

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.